Which medications in the drug class Rho Kinase/Norepinephrine Transporter Inhibitor are used in the treatment of Primary Open-Angle Glaucoma (POAG)?

Updated: Mar 16, 2020
  • Author: Kristin Schmid Biggerstaff, MD; Chief Editor: Inci Irak Dersu, MD, MPH  more...
  • Print

Rho Kinase/Norepinephrine Transporter Inhibitor

These agents increase aqueous humor outflow through the trabecular meshwork route. In December 2017, the FDA approved netarsudil, a first-in-class inhibitor of rho kinase and norepinephrine transporter, for the treatment of elevated intraocular pressure (IOP) caused by open-angle glaucoma or ocular hypertension. Approval was based on 2 phase III clinical trials (Rocket 1 and Rocket 2), which enrolled 1,167 patients. Patients were randomized to receive netarsudil once daily (Rocket 1 or Rocket 2) or BID (Rocket 2 only). Timolol was dosed BID in both studies. Treatment with netarsudil once daily produced clinically and statistically significant reductions of IOP from baseline (P< 0.001) and was noninferior to timolol in the per-protocol population with maximum baseline IOP < 25 mm Hg in both studies. [24]

Netarsudil ophthalmic (Rhopressa)

Indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!